Advances in cancer immunotherapy in solid tumors

Cancers

Volumn 8, Issue 12, 2016, Pages

  Menon, Smitha ^a   Shin, Sarah ^b   Dy, Grace ^c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cancer vaccines; CAR T cell therapy; Checkpoint inhibitors; Immune editing; Immunotherapy; T cell exhaustion; Tumor microenvironment

Indexed keywords

ACALABRUTINIB; ATEZOLIZUMAB; AVELUMAB; BMS 986016; DOCETAXEL; DURVALUMAB; ENOBLITUZUMAB; EPACADOSTAT; GWN 323; IBRUTINIB; INDOXIMOD; IPILIMUMAB; LIRILUMAB; LY 3022855; LY 3300054; MGD 61610588; MK 4166; MOGAMULIZUMAB; NECIITUMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PEXIDARTINIB; PF 04518600; RAMUCIRUMAB; TICILIMUMAB; TRX 518; UNCLASSIFIED DRUG; UNINDEXED DRUG; URELUMAB; UTOMILUMAB; VARLILUMAB;

ADAPTIVE IMMUNITY; ADVANCED CANCER; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TRANSFER; COLORECTAL CANCER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INNATE IMMUNITY; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MELANOMA; MERKEL CELL TUMOR; MESOTHELIOMA; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; NEOPLASM; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; REVIEW; SMALL CELL LUNG CANCER; SOLID TUMOR; TH1 CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UROGENITAL TRACT CANCER;

EID: 85005959718     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers8120106     Document Type: Review

References (100)

1. Klapper, J.A.; Downey, S.G.; Smitha, F.O.; Yang, J.C.; Hughes, M.S.; Kammula, U.S.; Shery, R.M.; Royal, R.E.; Steinberg, S.M.; Rosenberg, S. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma. Cancer 2008, 113, 293-301. [CrossRef] [PubMed]
2. Atzpodien, J.; Kirchner, H.; Rebmann, U.; Soder, M.; Gertenbach, U.; Siebels, M.; Roigas, J.; Raschke, R.; Salm, S.; Schwindi, B.; et al. Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: Results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br. J. Cancer 2006, 95, 463-469. [CrossRef] [PubMed]
3. Gogas, H.; Ioannovich, J.; Dafni, U.; Stavropoulou-Giokas, C.; Frangia, K.; Tsoutsos, D.; Panagiotou, P.; Polyzos, A.; Papadopoulos, O.; Stratigios, A.; et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 2006, 354, 709-718. [CrossRef] [PubMed]
4. Wolmark, N.; Rockette, H.; Mamounas, E.; Jones, J.;Wieand, S.;Wickerham, D.L.; Bear, H.D.; Atkins, J.N.; Dimitrov, N.V.; Glass, A.G.; et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C Carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J. Clin. Oncol. 1999, 17, 3553-3559. [PubMed]
5. Mungan, N.A.;Witjes, J.A. Bacille Calmette-Guérin in superficial transitional cell carcinoma. Br. J. Urol. 1998, 82, 213-223. [CrossRef] [PubMed]
6. Sylvester, R.J.; van der Meijden, A.P.;Witjes, J.A.; Kurth, K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials. J. Urol. 2005, 174, 86-91. [CrossRef] [PubMed]
7. Harding, F.A.; McArthur, J.G.; Gross, J.A.; Raulet, D.H.; Allison, J.P. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992, 356, 607-609. [CrossRef] [PubMed]
8. Tivol, E.A.; Borriello, F.; Schweitzer, A.N.; Lynch, W.P.; Bluestone, J.A.; Sharpe, A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3, 541-547. [CrossRef]
9. Keir, M.E.; Butte, M.J.; Freeman, G.J.; Sharpe, A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26, 677-704. [CrossRef] [PubMed]
10. Brahmer, J.; Reckamp, K.L.; Baas, P.; Crino, L.; Eberhardt, W.E.; Puddubskaya, E.; Antonia, S.; Pluzanski, A.; Vokes, E.E.; Holgado, E.; et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 2015, 373, 123-135. [CrossRef] [PubMed]
11. Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Hogado, E.; et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 2015, 373, 1627-1639. [CrossRef] [PubMed]
12. Garon, E.B.; Rizvi, N.A.; Hui, R.; Leighl, N.; Balmanoukian, A.S.; Eder, J.P.; Patnaik, A.; Aggarwal, C.; Gubens, M.; Horn, L.; et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015, 372, 2018-2028. [CrossRef] [PubMed]
13. Hodi, F.S.; O’Day, S.J.; McDermott, D.F.;Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadenorf, D.; Hassel, J.C.; et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711-723. [CrossRef] [PubMed]
14. Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science 2011, 331, 1565-1570. [CrossRef] [PubMed]
15. Fridman, W.H.; Pages, F.; Sautes-Fridman, C.; Galon, J. The immune contexture in human tumours: Impact on clinical outcome. Nat. Rev. Cancer 2012, 12, 298-306. [CrossRef] [PubMed]
16. Goc, J.; Germain, C.; Vo-Bourgais, T.K.; Lupo, A.; Klein, C.; Knockaert, S.; de Chaisemartin, L.; Ouakrim, H.; Becht, E.; Alifano, M.; et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 2014, 74, 705-715. [CrossRef] [PubMed]
17. Jiang, Y.; Li, Y.; Zhu, B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015, 6, e1792. [CrossRef] [PubMed]
18. Pauken, K.E.; Wherry, E.J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015, 36, 265-276. [CrossRef] [PubMed]
19. Zarour, H.M. Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin. Cancer Res. 2016, 22, 1856-1864. [CrossRef] [PubMed]
20. O’Day, S.J.; Hamid, O.; Urba,W.J. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4). Cancer 2007, 110, 2614-2627. [CrossRef] [PubMed]
21. Schildberg, F.A.; Klein, S.R.; Freeman, G.J.; Sharpe, A.H. Coinhibitory Pathways in the B7-CD28 ligand-receptor family. Immunity 2016, 44, 955-972. [CrossRef] [PubMed]
22. Topalian, S.L.; Drake, C.G.; Pardoll, D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 2012, 24, 207-212. [CrossRef] [PubMed]
23. Francisco, L.M.; Salinas, V.H.; Brown, K.E.; Vanguri, V.K.; Freeman, G.J.; Kuchroo, V.K.; Sharpe, A.H. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 2009, 206, 3015-3029. [CrossRef] [PubMed]
24. Buchbinder, E.I.; Desai, A. CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 2016, 39, 98-106. [CrossRef] [PubMed]
25. Robert, C.; Thomas, L.; Bondarenko, I.; O’Day, S.; Weber, J.; Garbe, C.; Lebbe, C.; Baurain, J.F.; Testori, A.; Grob, J.J.; et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364, 2517-2526. [CrossRef] [PubMed]
26. Robert, C.; Schachter, J.; Long, G.V.; Arance, A.; Grob, J.J.; Mortier, L.; Daud, A.; Carlino, M.S.; McNeil, C.; Lotem, M.; et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 2015, 372, 2521-2532. [CrossRef] [PubMed]
27. Robert, C.; Long, G.V.; Brady, B.; Dutriaux, C.; Maio, M.; Mortier, L.; Hassel, J.C.; Rutkowski, P.; McNeill, C.; Kalinka-Warzocha, E.; et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015, 372, 320-330. [PubMed]
28. Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Schadendorf, D.; Dummer, R.; Smylie, M.; Rutkowski, P.; et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 2015, 373, 23-34. [CrossRef] [PubMed]
29. Wolchok, J.D.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J.J.; Cowey, L.C.; Lao, C.; Schadendorf, D.; Ferucci, P.F.; Smylie, M. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J. Clin. Oncol. 2016, 34, Abstract 9505.
30. Long, G.V.; Atkinson, V.; Cebon, J.S.; Jameson, M.B.; Fitzharris, B.M.; McNeil, C.M.; Hill, A.G.; Ribas, A.; Atkins, M.B.; Thompson, J.A.; et al. Pembrolizumab (Pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort. J. Clin. Oncol. 2016, 34, Abstract 9506.
31. Eggermont, A.M.; Chiarion-Sileni, V.; Grob, J.J.; Dummer, R.; Wolchok, J.D.; Schmidt, H.; Hamid, O.; Robert, C.; Ascierto, P.A.; Richards, J.M.; et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. Lancet Oncol. 2015, 16, 522-530. [CrossRef]
32. Herbst, R.S.; Bass, P.; Kim, D.W.; Felip, E.; Perez-Gracia, J.L.; Han, J.Y.; Molina, J.; Kim, J.H.; Arvis, C.D.; Ahn, M.J.; et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016, 387, 1540-1550. [CrossRef]
33. Reck, M.; Rodriguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csoszi, T.; Fulop, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 2016, 375, 1823-1833. [CrossRef] [PubMed]
34. Antonia, S.J.; Lopez-Martin, J.A.; Bendell, J.C.; Ott, P.A.; Taylor, M.H.; Eder, J.P.; Jager, D.; Le, D.T.; De Braud, F.G.; Morse, M.; et al. Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC). J. Clin. Oncol. 2016, 34, Abstract 100.
35. Motzer, R.J.; Escudier, B.; McDermott, D.F.; George, S.; Hammers, H.J.; Srinivas, S.; Tykodi, S.S.; Sosman, J.A.; Procopio, G.; Pilmack, E.R.; et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 2015, 373, 1803-1813. [CrossRef] [PubMed]
36. Petrylak, D.P.; Powles, T.; Bellmunt, J.; Braiteh, F.S.; Loriot, Y.; Zambrano, C.C.; Burris, H.A.; Kim, J.W.; Teng, S.M.; Bruey, J.M.; et al. A Phase Ia Study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). J. Clin. Oncol. 2015, 33, Abstract 4501.
37. Rosenberg, J.E.; Hoffman-Censits, J.; Powles, T.; van der Heijden, M.S.; Balar, A.V.; Necchi, A.; Dawson, N.; O’Donnel, P.H.; Balmanoukian, A.; Loriot, Y.; et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 2016, 387, 1909-1920. [CrossRef]
38. Calabro, L.; Morra, A.; Fonsatti, E.; Cutaia, O.; Amato, G.; Giannarelli, D.; Di Giacomo, A.M.; Danielli, R.; Altomonte, M.; Mutti, L.; et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial. Lancet Oncol. 2013, 14, 1104-1111. [CrossRef]
39. Kindler, H.L.; Scherpereel, A.; Calabro, L.; Aerts, J.; Cedres-Perez, S.; Bearz, A.; Nackaerts, K.; Fennell, D.A.; Kowalski, D.; Tsao, A.S.; et al. Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study. J. Clin. Oncol. 2016, 34, Abstract 8502.
40. Alley, E.W.; Molife, L.R.; Santoro, A.; Beckey, K.; Yuan, S.; Cheng, J.D.; Piperdi, B.; Schellens, J.H.M. Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028. Cancer Res. 2015, 75, Abstract CT103. [CrossRef]
41. Nghiem, P.T.; Bhatia, S.; Lipson, E.J.; Kudchadkar, R.R.; Miller, N.J.; Annamalai, L.; Berry, S.; Chartash, E.K.; Daud, A.; Fling, S.P. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N. Engl. J. Med. 2016, 374, 2542-2552. [CrossRef] [PubMed]
42. Le, D.T.; Uram, J.N.; Wang, H.; Bartlett, B.R.; Kemberling, H.; Eyring, A.D.; Skora, A.D.; Luber, B.S.; Azad, N.S.; Laheru, D.; et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 2015, 372, 2509-2520. [CrossRef] [PubMed]
43. Seiwert, T.Y.; Haddad, R.; Gupta, S.; Mehra, R.; Tahra, M.; Berger, R.; Lee, S.H.; Burtness, B.; Le, D.T.; Heath, K.; et al. Antitumor Activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. J. Clin. Oncol. 2015, 33, Abstrat LBA6008.
44. Frenel, J.S.; Tourneau, C.L.; O’Neil, B.H.; Ott, P.A.; Piha-Paul, S.A.; Gomez-Roca, C.A.; Van Brummelen, E.; Rugo, H.S.; Thomas, S.; Saraf, S.; et al. Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study. J. Clin. Oncol. 2016, 34, Abstrat 5515.
45. Morris, V.K.; Ciombor, K.K.; Salem, M.E.; Nimeiri, H.S.; Iqbal, S.; Singh, P.P.; Polite, B.N.; Deming, D.A.; Chan, E.; Wade, J.L.; et al. NCI9673: A Multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA). J. Clin. Oncol. 2016, 34, Abstrat 3503.
46. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 378-390. [CrossRef] [PubMed]
47. Cheng, A.L.; Kang, Y.K.; Chen, Z.; Tsao, C.J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.S.; et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10, 25-34. [CrossRef]
48. Harding, J.J.; El Dika, I.; Abou-Alfa, G.K. Immunotherapy in hepatocellular carcinoma: Primed to make a difference? Cancer 2016, 122, 367-377. [CrossRef] [PubMed]
49. Wang, B.J.; Bao, J.J.; Wang, J.Z.; Wang, Y.; Jiang, M.; Xing, M.Y.; Zhang, W.G.; Qi, J.Y.; Roggendorf, M.; Lu, M.J.; et al. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J. Gastroenterol. 2011, 17, 3322-3329. [CrossRef] [PubMed]
50. El-Khoueiry, A.B.; Melero, I.; Crocenzi, T.S.;Welling, T.H.; Yau, T.C.; Yeo,W.; Chopra, A.; Gross, J.; Lang, L.; Anderson, J.; et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J. Clin. Oncol. 2015, 33, Abstrat LBA101.
51. Ansell, S.M.; Lesokhin, A.M.; Borrello, I.; Halwani, A.; Scott, E.C.; Gutierrez, M.; Schuster, S.J.; Millenson, M.M.; Cattry, D.; Freeman, G.J.; et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl. J. Med. 2015, 372, 311-319. [CrossRef] [PubMed]
52. Hodi, F.S.; Hwu, W.J.; Kefford, R.; Weber, J.S.; Daud, A.; Hamid, O.; Patnaik, A.; Ribas, A.; Robert, C.; Gangadhar, T.C.; et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J. Clin. Oncol. 2016, 34, 1510-1517. [CrossRef] [PubMed]
53. Gyorki, D.E.; Callahan, M.;Wolchok, J.D.; Ariyan, C.E. The delicate balance of melanoma immunotherapy. Clin. Transl. Immunol. 2013, 2, e5. [CrossRef] [PubMed]
54. Govindan, R.; Ding, L.; Griffith, M.; Subramanian, J.; Dees, N.D.; Kanchi, K.L.; Maher, C.A.; Fulton, R.; Fulton, L.; Wallis, J.; et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012, 150, 1121-1134. [CrossRef] [PubMed]
55. Rizvi, N.A.; Hellmann, M.D.; Snyder, A.; Kvistborg, P.; Makarov, V.; Havel, J.J.; Lee,W.; Yuan, J.;Wong, P.; Ho, T.S.; et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348, 124-128. [CrossRef] [PubMed]
56. Snyder, A.; Makarov, V.; Merghoub, T.; Yuan, J.; Zaretsky, J.M.; Desrichard, A.;Walsh, L.A.; Postow, M.A.; Wong, P.; Ho, T.S.; et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014, 371, 2189-2199. [CrossRef] [PubMed]
57. Chow, L.Q.M.; Mehra, R.; Haddad, R.; Mahipal, A.; Weiss, J.; Berger, R.; Eder, J.P.; Burtness, B.; Tahar, M.; Keam, B.; et al. Biomarkers and response to pembrolizumab (Pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J. Clin. Oncol. 2016, 34, Abstract 6010.
58. Doi, T. Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475). J. Clin. Oncol. 2016, 34, Abstract 4046.
59. Kataoka, K.; Shiraishi, Y.; Takeda, Y.; Sakata, S.; Matsumoto, M.; Nagano, S.; Maeda, T.; Nagata, Y.; Kitanaka, A.; Mizuno, S.; et al. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 2016, 534, 402-406. [CrossRef] [PubMed]
60. Yuan, J.; Hegde, P.S.; Clynes, R.; Foukas, P.G.; Harari, A.; Kleen, T.O.; Kvistborg, P.; Maccalli, C.; Maecker, H.T.; Page, D.B.; et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J. Immuno Ther. Cancer 2016, 4, 1-25. [CrossRef] [PubMed]
61. Weber, J.S.; Antonia, S.J.; Topalian, S.L.; Schadendorf, D.; Larkin, J.M.G.; Sznol, M.; Liu, H.Y.;Waxman, I.; Robert, C. Safety profile of nivolumab (NIVO) in patients (pts) with Advanced melanoma (MEL): A pooled analysis. J. Clin. Oncol. 2015, 33, Abstrat 9018.
62. Naidoo, J.; Page, D.B.; Li, B.T.; Connell, L.C.; Schindler, K.; Lacouture, M.E.; Postow, M.A.; Wolchok, J.D. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 2015, 26, 2375-2391. [CrossRef] [PubMed]
63. Champiat, S.; Lambotte, O.; Barreau, E.; Belkhir, R.; Berdelou, A.; Carbonnel, F.; Cauquil, C.; Chanson, P.; Collins, M.; Durrbach, A.; et al. Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. Ann. Oncol. 2016, 27, 559-574. [CrossRef] [PubMed]
64. Horvat, T.Z.; Adel, N.G.; Dang, T.O.; Momtaz, P.; Postow, M.A.; Callahan, M.K.; Carvajal, R.D.; Dickson, M.A.; D’Angelo, S.P.; Woo, K.M. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J. Clin. Oncol. 2015, 33, 3193-3198. [CrossRef] [PubMed]
65. Huang, R.Y.; Eppolito, C.; Lele, S.; Shrikant, P.; Matsuzaki, J.; Odunsi, K. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget 2015, 6, 27359-27377. [CrossRef] [PubMed]
66. Sakuishi, K.; Apetoh, L.; Sullivan, J.M.; Blazar, B.R.; Kuchroo, V.K.; Anderson, A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010, 207, 2187-2194. [CrossRef] [PubMed]
67. Infante, J.R.; Hansen, R.A.; Pishvaian, M.J.; Chow, L.Q.M.; McArthur, G.A.; Bauer, T.M.; Liu, S.V.; Sandhu, S.K.; Tsai, F.Y.-C.; Kim, J.; et al. A Phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors. J. Clin. Oncol. 2016, 34, Abstrat 101.
68. Tolcher, A.W.; Sznol, M.; Hu-Lieskovan, S.; Papadopoulos, K.P.; Patnaik, A.; Rasco, D.W.; Di Gravio, D.; Huang, B.; Gambhire, D.; Chen, Y.; et al. Phase Ib Study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors. J. Clin. Oncol. 2016, 34, Abstrat 3002.
69. Suntharalingam, G.; Perry, M.R.; Ward, S.; Brett, S.J.; Castello-Cortes, A.; Brunner, M.D.; Panoskaltsis, N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 2006, 355, 1018-1028. [CrossRef] [PubMed]
70. Chang, C.L.; Hsu, Y.T.; Wu, C.C.; Lai, Y.Z.; Wang, C.; Yang, Y.C.; Wu, T.C.; Hung, C.F. Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res. 2013, 73, 119-127. [CrossRef] [PubMed]
71. Rizvi, N.A.; Hellmann, M.D.; Brahmer, J.R.; Juergens, R.A.; Borghaei, H.; Gettinger, S.; Chow, L.Q.; Gerber, D.E.; Laurie, S.A.; Goldman, J.W.; et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 2016, 34, 2969-2979. [CrossRef] [PubMed]
72. Demaria, S.; Ng, B.; Devitt, M.L.; Babb, J.S.; Kawashima, N.; Liebes, L.; Formenti, S.C. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 862-870. [CrossRef] [PubMed]
73. Krcik, E.M. Radiation Therapy Plus Anti-Programmed Death Ligand 1 Immunotherapy: A Review on Overall Survival. Radiol. Technol. 2016, 88, 123-128. [PubMed]
74. Hellmann, M.D.; Friedman, C.F.; Wolchok, J.D. Chapter Six-Combinatorial Cancer Immunotherapies. In Advances in Immunology; Robert, D.S., Ed.; Academic Press: Cambridge, MA, USA, 2016; pp. 251-277.
75. Holmgaard, R.B.; Zamarin, D.; Munn, D.H.; Wolchok, J.D.; Allison, J.P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 2013, 210, 1389-1402. [CrossRef] [PubMed]
76. Leone, R.D.; Lo, Y.C.; Powell, J.D. A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comput. Struct. Biotechnol. J. 2015, 13, 265-272. [CrossRef] [PubMed]
77. Joncker, N.T.; Raulet, D.H. Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells. Immunol. Rev. 2008, 224, 85-97. [CrossRef] [PubMed]
78. Long, E.O. Negative signaling by inhibitory receptors: The NK cell paradigm. Immunol. Rev. 2008, 224, 70-84. [CrossRef] [PubMed]
79. Romagné, F.; André, P.; Spee, P.; Zahn, S.; Anfossi, N.; Gauthier, L.; Capanni, M.; Ruggeri, L.; Benson, D.M., Jr.; Blaser, B.W.; et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009, 114, 2667-2677. [CrossRef] [PubMed]
80. Holmgaard, R.B.; Zamarin, D.; Lesokhin, A.; Merghoub, T.; Wolchok, J.D. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine 2016, 6, 50-58. [CrossRef] [PubMed]
81. Chang, D.K.; Peterson, E.; Sun, J.; Goudie, C.; Drapkin, R.I.; Liu, J.F.; Matulonis, U.; Zhu, Q.; Marasco,W.A. Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology 2016, 5, e1090075. [CrossRef] [PubMed]
82. Duvic, M.; Pinter-Brown, L.C.; Foss, F.M.; Sokol, L.; Jorgensen, J.L.; Challagundla, P.; Dwyer, K.M.; Zhang, X.; Kurman, M.R.; Ballerini, R.; et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood 2015, 125, 1883-1889. [CrossRef] [PubMed]
83. Ponader, S.; Burger, J.A. Bruton’s tyrosine kinase: From X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J. Clin. Oncol. 2014, 32, 1830-1839. [CrossRef] [PubMed]
84. Sagiv-Barfi, I.; Kohrt, H.E.; Czerwinski, D.K.; Ng, P.P.; Chang, B.Y.; Levy, R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc. Natl. Acad. Sci. USA 2015, 112, E966-E972. [CrossRef] [PubMed]
85. Bellucci, R.; Martin, A.; Bommarito, D.; Wang, K.; Hansen, S.H.; Freeman, G.J.; Ritz, J. Interferon-gamma-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology 2015, 4, e1008824. [CrossRef] [PubMed]
86. Frankel, S.R.; Baeuerle, P.A. Targeting T cells to tumor cells using bispecific antibodies. Curr. Opin. Chem. Biol. 2013, 17, 385-392. [CrossRef] [PubMed]
87. Goebeler, M.E.; Bargou, R. Blinatumomab: A CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leuk. Lymphoma 2016, 57, 1021-1032. [CrossRef] [PubMed]
88. Rosenberg, S.A.; Restifo, N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015, 348, 62-68. [CrossRef] [PubMed]
89. Rosenberg, S.A.; Yang, J.C.; Sherry, R.M.; Kammula, U.S.; Hughes, M.S.; Phan, G.Q.; Citrin, D.E.; Restifo, N.P.; Robbins, P.F.; Wunderlich, J.R.; et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011, 17, 4550-4557. [CrossRef] [PubMed]
90. Stevanovic, S.; Draper, L.M.; Langhan, M.M.; Campbell, T.E.; Kwong, M.L.; Wunderlich, J.R.; Dudley, M.E.; Yang, J.C.; Sherry, R.M.; Kammula, U.S.; et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J. Clin. Oncol. 2015, 33, 1543-1550. [CrossRef] [PubMed]
91. Sadelain, M.; Riviere, I.; Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 2003, 3, 35-45. [CrossRef] [PubMed]
92. Curran, K.J.; Pegram, H.J.; Brentjens, R.J. Chimeric antigen receptors for T cell immunotherapy: Current understanding and future directions. J. Gene Med. 2012, 14, 405-415. [CrossRef] [PubMed]
93. Klebanoff, C.A.; Rosenberg, S.A.; Restifo, N.P. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat. Med. 2016, 22, 26-36. [CrossRef] [PubMed]
94. Park, J.H.; Brentjens, R.J. Are all chimeric antigen receptors created equal? J. Clin. Oncol. 2015, 33, 651-653. [CrossRef] [PubMed]
95. Guillerey, C.; Huntington, N.D.; Smyth, J. Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 2016, 17, 1025-1036. [CrossRef] [PubMed]
96. Du, S.H.; Li, Z.; Chen, C.; Tan, W.K.; Chi, Z.; Kwang, T.W.; Xu, X.H.; Wang, S. Co-expansion of cytokine-induced killer cells and Vgamma9Vdelta2 T cells for CAR T-cell. Therapy. PLoS ONE 2016, 11, e0161820.
97. Lin, Y.; Okada, H. Cellular immunotherapy for malignant gliomas. Expert Opin. Biol. Ther. 2016, 16, 1265-1275. [CrossRef] [PubMed]
98. Leuci, V.; Mesiano, G.; Gammaitoni, L.; Todorovic, M.; Giraudo, L.; Carnevale-Schianca, F.; Aglietta, M.; Sangiolo, D. Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy. Anticancer Agents Med. Chem. 2014, 14, 211-222. [CrossRef] [PubMed]
99. Kochenderfer, J.N.; Dudley, M.E.; Kassim, S.H.; Somerville, R.P.; Carpenter, R.O.; Stetler-Stevenson, M.; Yang, J.C.; Phan, G.Q.; Hughes, M.S.; Sherry, R.M.; et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 2015, 33, 540-549. [CrossRef] [PubMed]
100. Adusumilli, P.S.; Cherkassky, L.; Villena-Vargas, J.; Colovos, C.; Servais, E.; Plotkin, J.; Jones, D.R.; Sadelain, M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 2014. [CrossRef] [PubMed]